Closing in on the target: Sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy

Clinical Infectious Diseases

Volumn 56, Issue 10, 2013, Pages 1466-1470

  Lontok, Erik ^a   Mani, Nina ^a   Harrington, Patrick R ^b   Miller, Veronica ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

direct acting antiviral (DAA); hepatitis C virus (HCV); lower limit of quantitation (LLOQ)

Indexed keywords

BOCEPREVIR; TELAPREVIR; VIRUS RNA;

ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS RNA ASSAY; HUMAN; LIMIT OF DETECTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIMIT OF DETECTION; OLIGOPEPTIDES; PROLINE; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84877311111     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit025     Document Type: Article

References (37)

1. Chak E, Talal A, Sherman K, Schiff E, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31:1090-101.
2. Armstrong G, Wasley A, Simard E, McQuillan G, Kuhnert W, Alter M. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
4. Mitchell A, Colvin H, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51:729-33.
5. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V; on behalf of the Definitions/Nomenclature Working Group of the HCV Drug Development Advisory Group. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012; 56:2398-403.
6. Ferenci P, Fried M, Shiffman M, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-33.
7. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
8. Jensen D, Morgan T, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-60.
9. Buti M, Esteban R. 1990-2010: two decades of interferon-based therapy. Clin Liver Dis 2011; 15:473-82.
10. Food and Drug Administration. Telaprevir product insert. 2012. http://wwwaccessdatafdagov/drugsatfda-docs/label/2012/201917s004lblpdf. Accessed 1 August 2012.
11. Poordad F, McCone J Jr, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
12. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
13. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
15. Jacobson I, Pawlotsky J, Afdhal N, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19(suppl 2):1-26.
16. US Food and Drug Administration. Boceprevir product insert. 2012. http://wwwaccessdatafdagov/drugsatfda-docs/label/2012/202258S005pdf. Accessed 1 August 2012.
17. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54:96-104.
18. Harrington P, Zeng W, Naeger L. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55:1048-57.
19. Vermehren J, Yu M, Monto A, et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011; 52:133-7.
20. Ross R, Viazov S, Sarr S, Hoffmann S, Kramer A, Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNAbased signal amplification assay. J Virol Methods 2002; 101:159-68.
21. Sarrazin C, Dragan A, Gartner B, et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 2008; 43:162-8.
22. Martinot-Peignoux M, Khiri H, Leclere L, Maylin S, Marcellin P, Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. J Clin Virol 2009; 46:216-21.
23. Ghany M, Nelson D, Strader D, Thomas D, Seeff L. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
24. Cobb B, Vilchez R. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. Hepatology 2012; 55: 979-80; author reply 80-1.
25. Armbruster D, Tillman M, Hubbs L. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 1994; 40(7 Pt 1):1233-8.
26. Linnet K, Kondratovich M. Partly nonparametric approach for determining the limit of detection. Clin Chem 2004; 50:732-40.
27. Laperche S, Bouchardeau F, Andre-Garnier E, et al. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J Clin Microbiol 2011; 49:1113-5.
28. Fevery B, Susser S, Lenz O, et al. Comparison of two quantitative HCV RNA assays in samples from patients treated with a protease inhibitor-based therapy: implications for response guided therapy. J Hepatol 2012; 56(suppl 2):S26.
29. Abbott RealTime HCV Package insert. Des Plaines, IL: Abbott Molecular, May 2011.
30. Roche COBAS Ampliprep and COBAS Taqman HCV Test 2.0. Pleasanton, CA: Roche Molecular, October 2011.
31. Fried M, Hadziyannis S, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
32. Harrington P, Naeger L, Zeng W. O'Sullivan et al., Letter to the Editor. Hepatology 2012.
33. Scott L, Perry C. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62:507-56.
34. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.
35. McHutchison J. Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol 2002; 17:431-41.
36. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(suppl 1):i36-46.
37. Cooper C. Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting. Clin Infect Dis 2012; 55:418-25.